See also this year's filing and all EDGAR filings for this company.
PDF Report 0001274792_2018_Merrimack_Pharmaceuticals_INC.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| warning | Missing logo | subcommand.report | {} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)': 21, '100040 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)2': 2}} |
Graph
Absolute values for 0001274792, Merrimack Pharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 95,046,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 6,467,000 |
| 3 | remainder_Assets | 15,813,000 |
| 4 | LiabilitiesCurrent | 19,777,000 |
| 5 | LiabilitiesNoncurrent | 56,000 |
| 6 | remainder_Liabilities | 1,209,000 |
| 7 | CostOfGoodsAndServicesSold | 6,911,069 |
| 8 | SellingGeneralAndAdministrativeExpense | 33,726,183 |
| 9 | ResearchAndDevelopmentExpense | 52,504,297 |
| 10 | remainder_Expenses | 49,399,890 |
| 11 | remainder_Revenues | 143,595,632 |
| 12 | remainder_NetIncome | 21,931,414 |
| 13 | remainder_ComprehensiveNetIncome | 1,392,824 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 117,326,000 |
| 1 | Liabilities | 21,042,000 |
| 2 | Expenses | 142,541,439 |
| 3 | Revenues | 143,595,632 |
| 4 | StockholdersEquity | 96,284,000 |
| 5 | NetIncome | 22,985,607 |
| 6 | ComprehensiveNetIncome | 23,682,019 |
| 7 | BaseVar | 223,914,654 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 3.38 |
| 9 | EconomicCapitalRatio | 3.94 |
Edgar->Model Mapping
Feature Distribution
Change over Time
